These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 8914032

  • 1. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group.
    Breyer JA, Bain RP, Evans JK, Nahman NS, Lewis EJ, Cooper M, McGill J, Berl T.
    Kidney Int; 1996 Nov; 50(5):1651-8. PubMed ID: 8914032
    [Abstract] [Full Text] [Related]

  • 2. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
    Laffel LM, McGill JB, Gans DJ.
    Am J Med; 1995 Nov; 99(5):497-504. PubMed ID: 7485207
    [Abstract] [Full Text] [Related]

  • 3. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM, RENAAL Study Group.
    Arch Intern Med; 2003 Jul 14; 163(13):1555-65. PubMed ID: 12860578
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study.
    Gall MA, Hougaard P, Borch-Johnsen K, Parving HH.
    BMJ; 1997 Mar 15; 314(7083):783-8. PubMed ID: 9080995
    [Abstract] [Full Text] [Related]

  • 5. Sequential renal biopsies in insulin-dependent diabetic patients: structural factors associated with clinical progression.
    Fioretto P, Steffes MW, Sutherland DE, Mauer M.
    Kidney Int; 1995 Dec 15; 48(6):1929-35. PubMed ID: 8587254
    [Abstract] [Full Text] [Related]

  • 6. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.
    Rossing P, Hougaard P, Borch-Johnsen K, Parving HH.
    BMJ; 1996 Sep 28; 313(7060):779-84. PubMed ID: 8842069
    [Abstract] [Full Text] [Related]

  • 7. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
    Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJ, Vart P, Wolffenbuttel BH, Umanath K, Lewis JB, de Zeeuw D, Gansevoort RT.
    Am J Kidney Dis; 2015 Sep 28; 66(3):450-8. PubMed ID: 25987260
    [Abstract] [Full Text] [Related]

  • 8. Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria?
    Mogensen CE.
    Diabetes; 1990 Jul 28; 39(7):761-7. PubMed ID: 2191882
    [Abstract] [Full Text] [Related]

  • 9. Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.
    Galsgaard J, Persson F, Hansen TW, Jorsal A, Tarnow L, Parving HH, Rossing P.
    Kidney Int; 2017 Nov 28; 92(5):1242-1248. PubMed ID: 28712855
    [Abstract] [Full Text] [Related]

  • 10. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
    Rodby RA, Firth LM, Lewis EJ.
    Diabetes Care; 1996 Oct 28; 19(10):1051-61. PubMed ID: 8886549
    [Abstract] [Full Text] [Related]

  • 11. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar 28; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 12. Value of adding the renal pathological score to the kidney failure risk equation in advanced diabetic nephropathy.
    Yamanouchi M, Hoshino J, Ubara Y, Takaichi K, Kinowaki K, Fujii T, Ohashi K, Mise K, Toyama T, Hara A, Kitagawa K, Shimizu M, Furuichi K, Wada T.
    PLoS One; 2018 Mar 28; 13(1):e0190930. PubMed ID: 29338014
    [Abstract] [Full Text] [Related]

  • 13. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD.
    N Engl J Med; 1993 Nov 11; 329(20):1456-62. PubMed ID: 8413456
    [Abstract] [Full Text] [Related]

  • 14. Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients.
    Wirta OR, Pasternack AI, Mustonen JT, Koivula TA, Harmoinen A.
    Nephrol Dial Transplant; 1996 Mar 11; 11(3):449-56. PubMed ID: 8671814
    [Abstract] [Full Text] [Related]

  • 15. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study.
    Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F.
    BMJ; 1996 Sep 07; 313(7057):591-4. PubMed ID: 8806248
    [Abstract] [Full Text] [Related]

  • 16. Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria.
    Okada T, Nagao T, Matsumoto H, Nagaoka Y, Wada T, Nakao T.
    Nephrology (Carlton); 2012 Jan 07; 17(1):68-75. PubMed ID: 21933307
    [Abstract] [Full Text] [Related]

  • 17. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.
    Kidney Int; 2004 Jun 07; 65(6):2309-20. PubMed ID: 15149345
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.
    Ann Intern Med; 2003 Apr 01; 138(7):542-9. PubMed ID: 12667024
    [Abstract] [Full Text] [Related]

  • 19. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.
    Nephrol Dial Transplant; 2000 Apr 01; 15(4):487-97. PubMed ID: 10727543
    [Abstract] [Full Text] [Related]

  • 20. Factors associated with progression of diabetic nephropathy in Japanese elderly patients with type 2 diabetes: sub-analysis of the Japanese Elderly Diabetes Intervention Trial.
    Araki S, Nishio Y, Araki A, Umegaki H, Sakurai T, Iimuro S, Ohashi Y, Uzu T, Maegawa H, Kashiwagi A, Ito H, Japanese Elderly Intervention Trial Research Group.
    Geriatr Gerontol Int; 2012 Apr 01; 12 Suppl 1():127-33. PubMed ID: 22435948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.